Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
BlackRock, Inc. reported a passive ownership position in First Tracks Biotherapeutics Inc. common stock. BlackRock beneficially owns 1,919,376 shares, representing 5.5% of the class. It has sole voting power over 1,886,631 shares and sole dispositive power over all 1,919,376 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of First Tracks Biotherapeutics’ outstanding common shares.
First Tracks Biotherapeutics, Inc. entered into a new sublease on June 15, 2026 with AnaptysBio, Inc. for approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, California.
The initial sublease term runs for 12 months, with an option to extend for up to an additional period ending no later than April 4, 2028, if the company gives at least three months’ prior written notice. The company may also terminate the sublease at any time during the term with three months’ prior written notice.
Monthly payments under the sublease equal the Basic Rent and Additional Rent AnaptysBio owes under the existing master lease, and the company is responsible for charges for services it requests. The sublease is subordinate to the master lease and will end if AnaptysBio’s lease or right to possess the premises terminates.
First Tracks Biotherapeutics director Rita Jain exercised equity awards to acquire additional common shares. On June 15, 2026, she acquired 7,330 shares of common stock through the exercise or conversion of restricted stock units at no cash exercise price, increasing her direct holdings to 19,194 shares.
The filing shows two RSU tranches of 1,300 and 6,030 units converting into common stock. Footnotes explain that each RSU represents a contingent right to receive one share upon settlement for no consideration, with vesting tied to continued service through June 15, 2026.
First Tracks Biotherapeutics director John P. Schmid exercised restricted stock units into common shares. On June 15, 2026, he acquired 6,030 shares of Common Stock at a reported price of $0.00 per share through an RSU conversion. Following this transaction, he directly holds 37,652 shares of Common Stock. The RSU award represented a contingent right to receive one share of Common Stock per unit upon settlement for no consideration.
First Tracks Biotherapeutics director John A. Orwin exercised restricted stock units to acquire 6,030 shares of Common Stock. The derivative exercise occurred on June 15, 2026 at an exercise price of $0.00 per share, increasing his direct holdings to 16,695 Common Stock shares.
The transaction reflects settlement of an RSU award, where each RSU represented a contingent right to receive one share of Common Stock for no consideration. The RSUs vested 100% on June 15, 2026, subject to his continued service to the company on that vesting date.
First Tracks Biotherapeutics director Ware J. Anthony exercised restricted stock units into common shares. On June 15, 2026, 6,030 Restricted Stock Units converted into 6,030 shares of Common Stock at no cost upon vesting. Following this settlement, he directly holds 15,660 common shares. No shares were sold in this filing.
First Tracks Biotherapeutics director Magda Marquet exercised restricted stock units into common shares. On June 15, 2026, she converted 6,030 restricted stock units into 6,030 shares of common stock for no cash consideration, reflecting compensation rather than a market purchase or sale.
Following the transaction, she directly owns 15,960 shares of common stock. The RSU award vested 100% on June 15, 2026, contingent on her continued service to the company through that date.
First Tracks Biotherapeutics director Dennis M. Fenton exercised restricted stock units into common shares as part of his equity compensation. On June 15, 2026, 6,030 RSUs converted into 6,030 shares of common stock at no cash cost, bringing his direct holdings to 10,995 shares. The RSUs vested in full on that date, with no remaining RSU balance reported.
First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026.
He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full at the company’s 2027 annual meeting of shareholders, if he continues providing service through that date.
First Tracks Biotherapeutics director Rita Jain received new equity awards. On May 12, 2026, she was granted options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026. She also received 2,500 restricted stock units, each convertible into one share of common stock, which vest in full on the date of the company’s 2027 annual meeting of shareholders, in both cases contingent on continued service.